FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1479873883> ?p ?o ?g. }

• W1479873883 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAIn eukaryotic cells, mRNA translation is restricted by the translation initiation step, in which eIF4E has been regarded as a master regulator. Overexpression of eIF4E has been found in different cancer types; however, whether eIF4E is involved in melanoma tumorigenesis and resistance to standard of care in melanoma remains unclear. We hypothesize that eIF4E promotes melanoma cell proliferation and facilitates the development of acquired resistance to the B-raf inhibitor, Vemurafenib. From our preliminary data, we show that eIF4E is overexpressed in a panel of malignant melanoma cell lines compared to immortalized melanocytes Mel ST. By genetically knocking down eIF4E via siRNA, we can significantly repress the proliferation of a subset of melanoma cell lines and decrease the level of the eIF4E downstream target Cyclin D1. In addition, the B-raf inhibitor Vemurafenib can drastically inhibit 4EBP-1 phosphorylation in BRAFV600E melanoma cell lines, and further cap binding analysis confirmed that Vemurafenib stabilizes the eIF4E - 4EBP-1 association in these cell lines.. In contrast, 4EBP-1 is highly phosphorylated in all Vemurafenib resistant cell lines, compared to the parental A375, even in the presence of Vemurafenib. Furthermore, cap binding assay show that, unlike their parental counterpart, four out of six resistant lines exhibit weak eIF4E - 4EBP-1 association even in the presence of Vemurafenib. This may imply that more free eIF4E is available for cap-dependent translation initiation in Vemu resistant lines compared to the parental A375. Besides, eIF4E activity contributes to the proliferation of some melanoma cell lines with acquired resistance to Vemurafenib, since siRNA-silencing eIF4E decreases their proliferation. In conclusion, our data show that eIF4E promotes proliferation of some melanoma cell lines and may be involved in maintaining the survival of some melanoma cell lines with acquired vemurafenib resistance. These data suggest that therapeutically targeting eIF4E may be a viable means of inhibiting melanoma cell proliferation and overcoming Vemurafenib resistance.Citation Format: Yao Zhan, Michael S. Dahabieh, Filippa Pettersson, Monica C. Dobocan, Marie Noel M. Boutchou, Leon Van Kempen, Sonia V. del Rincon, Wilson H. Miller, Jr.. The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3710. doi:10.1158/1538-7445.AM2014-3710" @default.
• W1479873883 created "2016-06-24" @default.
• W1479873883 creator A5010774811 @default.
• W1479873883 creator A5012915886 @default.
• W1479873883 creator A5019294769 @default.
• W1479873883 creator A5046040974 @default.
• W1479873883 creator A5048013287 @default.
• W1479873883 creator A5068432485 @default.
• W1479873883 creator A5075360364 @default.
• W1479873883 creator A5089111286 @default.
• W1479873883 date "2014-09-30" @default.
• W1479873883 modified "2023-09-26" @default.
• W1479873883 title "Abstract 3710: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma" @default.
• W1479873883 doi "https://doi.org/10.1158/1538-7445.am2014-3710" @default.
• W1479873883 hasPublicationYear "2014" @default.
• W1479873883 type Work @default.
• W1479873883 sameAs 1479873883 @default.
• W1479873883 citedByCount "0" @default.
• W1479873883 crossrefType "proceedings-article" @default.
• W1479873883 hasAuthorship W1479873883A5010774811 @default.
• W1479873883 hasAuthorship W1479873883A5012915886 @default.
• W1479873883 hasAuthorship W1479873883A5019294769 @default.
• W1479873883 hasAuthorship W1479873883A5046040974 @default.
• W1479873883 hasAuthorship W1479873883A5048013287 @default.
• W1479873883 hasAuthorship W1479873883A5068432485 @default.
• W1479873883 hasAuthorship W1479873883A5075360364 @default.
• W1479873883 hasAuthorship W1479873883A5089111286 @default.
• W1479873883 hasConcept C104317684 @default.
• W1479873883 hasConcept C105580179 @default.
• W1479873883 hasConcept C149364088 @default.
• W1479873883 hasConcept C161295673 @default.
• W1479873883 hasConcept C2776131300 @default.
• W1479873883 hasConcept C2777658100 @default.
• W1479873883 hasConcept C2994587330 @default.
• W1479873883 hasConcept C502942594 @default.
• W1479873883 hasConcept C54355233 @default.
• W1479873883 hasConcept C62112901 @default.
• W1479873883 hasConcept C71924100 @default.
• W1479873883 hasConcept C81885089 @default.
• W1479873883 hasConcept C86803240 @default.
• W1479873883 hasConceptScore W1479873883C104317684 @default.
• W1479873883 hasConceptScore W1479873883C105580179 @default.
• W1479873883 hasConceptScore W1479873883C149364088 @default.
• W1479873883 hasConceptScore W1479873883C161295673 @default.
• W1479873883 hasConceptScore W1479873883C2776131300 @default.
• W1479873883 hasConceptScore W1479873883C2777658100 @default.
• W1479873883 hasConceptScore W1479873883C2994587330 @default.
• W1479873883 hasConceptScore W1479873883C502942594 @default.
• W1479873883 hasConceptScore W1479873883C54355233 @default.
• W1479873883 hasConceptScore W1479873883C62112901 @default.
• W1479873883 hasConceptScore W1479873883C71924100 @default.
• W1479873883 hasConceptScore W1479873883C81885089 @default.
• W1479873883 hasConceptScore W1479873883C86803240 @default.
• W1479873883 hasLocation W14798738831 @default.
• W1479873883 hasOpenAccess W1479873883 @default.
• W1479873883 hasPrimaryLocation W14798738831 @default.
• W1479873883 hasRelatedWork W1508313146 @default.
• W1479873883 hasRelatedWork W1985050876 @default.
• W1479873883 hasRelatedWork W2034132874 @default.
• W1479873883 hasRelatedWork W2063795684 @default.
• W1479873883 hasRelatedWork W2086266172 @default.
• W1479873883 hasRelatedWork W2312543879 @default.
• W1479873883 hasRelatedWork W2535510152 @default.
• W1479873883 hasRelatedWork W2740076717 @default.
• W1479873883 hasRelatedWork W2808920109 @default.
• W1479873883 hasRelatedWork W2883520064 @default.
• W1479873883 hasRelatedWork W2885377179 @default.
• W1479873883 hasRelatedWork W2906508805 @default.
• W1479873883 hasRelatedWork W2967676932 @default.
• W1479873883 hasRelatedWork W2982128960 @default.
• W1479873883 hasRelatedWork W2986517130 @default.
• W1479873883 hasRelatedWork W3010076376 @default.
• W1479873883 hasRelatedWork W3030861018 @default.
• W1479873883 hasRelatedWork W3126594561 @default.
• W1479873883 hasRelatedWork W3178919840 @default.
• W1479873883 hasRelatedWork W986753386 @default.
• W1479873883 isParatext "false" @default.
• W1479873883 isRetracted "false" @default.
• W1479873883 magId "1479873883" @default.
• W1479873883 workType "article" @default.